Mounjaro has surpassed Keytruda to become the world's best-selling medicine, driven by booming demand for obesity and diabetes treatments. Experts say the rise of GLP-1 and dual-action metabolic drugs signals a major healthcare shift, with obesity increasingly treated as a chronic disease requiring long-term medical management worldwide.